Thus, CDH17 constitutes a promising therapeutic candidate for preventing metastatic progression in CRC by using either specific monoclonal antibodies against the RGD motif of CDH17 [21], CAR-T cells [22], or an anti-NLV peptide blocking CDH17/DSC1 binding [19]. This evidence concerns the gene CDH17 and colorectal carcinoma.